Shots: The P-III POLO study involves assessing of Lynparza (olaparib, 300mg, bid) vs PBO in 154 patients in ratio (3:2) with BRCAm metastatic pancreatic cancer whose disease had not progressed on 1st-line Pt-based CT The P-III POLO study results: improvement in PFS (7.4 vs 3.8mos.); @1yr & 2yrs. no disease progression ( 34% & 22% […]Read More
